News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
650,259 Results
Type
Article (53348)
Company Profile (181)
Press Release (596730)
Multimedia
Podcasts (79)
Webinars (11)
Section
Business (184325)
Career Advice (2773)
Deals (33804)
Drug Delivery (115)
Drug Development (79308)
Employer Resources (169)
FDA (16535)
Job Trends (15326)
News (323064)
Policy (32777)
Tag
Academia (2854)
Accelerated approval (6)
Adcomms (28)
Allergies (92)
Alliances (46810)
ALS (94)
Alzheimer's disease (1437)
Antibody-drug conjugate (ADC) (145)
Approvals (16501)
Artificial intelligence (279)
Autoimmune disease (27)
Automation (16)
Bankruptcy (349)
Best Places to Work (11654)
BIOSECURE Act (19)
Biosimilars (118)
Biotechnology (127)
Bladder cancer (83)
Brain cancer (31)
Breast cancer (296)
Cancer (2339)
Cardiovascular disease (197)
Career advice (2340)
Career pathing (33)
CAR-T (166)
Cell therapy (453)
Cervical cancer (20)
Clinical research (64726)
Collaboration (876)
Company closure (1)
Compensation (259)
Complete response letters (30)
COVID-19 (2835)
CRISPR (45)
C-suite (256)
Cystic fibrosis (107)
Data (2208)
Decentralized trials (2)
Denatured (21)
Depression (54)
Diabetes (286)
Diagnostics (6478)
Digital health (19)
Diversity (3)
Diversity, equity & inclusion (41)
Drug discovery (125)
Drug pricing (116)
Drug shortages (29)
Duchenne muscular dystrophy (100)
Earnings (70811)
Editorial (45)
Employer branding (22)
Employer resources (149)
Events (88483)
Executive appointments (760)
FDA (17818)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (768)
Gene editing (112)
Generative AI (25)
Gene therapy (335)
GLP-1 (818)
Government (4804)
Grass and pollen (6)
Guidances (67)
Healthcare (18976)
Huntington's disease (25)
IgA nephropathy (30)
Immunology and inflammation (141)
Indications (29)
Infectious disease (2992)
Inflammatory bowel disease (142)
Inflation Reduction Act (8)
Influenza (55)
Intellectual property (100)
Interviews (515)
IPO (15054)
IRA (43)
Job creations (4055)
Job search strategy (1952)
Kidney cancer (11)
Labor market (32)
Layoffs (535)
Leadership (24)
Legal (7537)
Liver cancer (81)
Lung cancer (333)
Lymphoma (155)
Machine learning (7)
Management (60)
Manufacturing (320)
MASH (71)
Medical device (13454)
Medtech (13459)
Mergers & acquisitions (19259)
Metabolic disorders (756)
Multiple sclerosis (85)
NASH (21)
Neurodegenerative disease (110)
Neuropsychiatric disorders (32)
Neuroscience (2016)
NextGen: Class of 2025 (6816)
Non-profit (4868)
Now hiring (32)
Obesity (409)
Opinion (251)
Ovarian cancer (76)
Pain (95)
Pancreatic cancer (82)
Parkinson's disease (155)
Partnered (20)
Patents (230)
Patient recruitment (111)
Peanut (50)
People (55321)
Pharmaceutical (35)
Pharmacy benefit managers (20)
Phase I (20096)
Phase II (28276)
Phase III (21672)
Pipeline (1232)
Policy (159)
Postmarket research (2586)
Preclinical (7879)
Press Release (63)
Prostate cancer (108)
Psychedelics (35)
Radiopharmaceuticals (236)
Rare diseases (411)
Real estate (5750)
Recruiting (70)
Regulatory (22649)
Reports (35)
Research institute (2523)
Resumes & cover letters (424)
Rett syndrome (5)
RNA editing (4)
RSV (50)
Schizophrenia (78)
Series A (138)
Series B (88)
Service/supplier (10)
Sickle cell disease (56)
Special edition (17)
Spinal muscular atrophy (156)
Sponsored (27)
Startups (3594)
State (2)
Stomach cancer (15)
Supply chain (73)
Tariffs (43)
The Weekly (56)
Vaccines (803)
Venture capitalists (43)
Weight loss (285)
Women's health (32)
Worklife (20)
Date
Last 7 days (829)
Last 30 days (2345)
Last 365 days (31103)
2025 (10267)
2024 (33563)
2023 (38279)
2022 (48997)
2021 (53442)
2020 (53155)
2019 (46988)
2018 (36089)
2017 (32833)
2016 (31882)
2015 (36111)
2014 (27762)
2013 (22934)
2012 (24678)
2011 (25438)
2010 (22771)
Location
Africa (936)
Alabama (56)
Alaska (7)
Arizona (182)
Arkansas (14)
Asia (38922)
Australia (6669)
California (5897)
Canada (1804)
China (507)
Colorado (265)
Connecticut (260)
Delaware (120)
Europe (89045)
Florida (827)
Georgia (194)
Hawaii (1)
Idaho (59)
Illinois (531)
India (26)
Indiana (300)
Iowa (9)
Japan (157)
Kansas (96)
Kentucky (26)
Louisiana (11)
Maine (69)
Maryland (849)
Massachusetts (3937)
Michigan (215)
Minnesota (361)
Mississippi (2)
Missouri (84)
Montana (30)
Nebraska (25)
Nevada (58)
New Hampshire (69)
New Jersey (1571)
New Mexico (30)
New York (1625)
North Carolina (941)
North Dakota (9)
Northern California (2511)
Ohio (189)
Oklahoma (13)
Oregon (34)
Pennsylvania (1206)
Puerto Rico (12)
Rhode Island (32)
South America (1299)
South Carolina (21)
South Dakota (1)
Southern California (2268)
Tennessee (98)
Texas (819)
United States (21426)
Utah (190)
Virginia (145)
Washington D.C. (62)
Washington State (524)
West Virginia (3)
Wisconsin (52)
650,259 Results for "ferring holding sa".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting
RELIEF THERAPEUTICS Holding SA announces the results of its annual general meeting (AGM) of shareholders, which took place in Geneva today.
June 27, 2024
·
3 min read
Duchenne muscular dystrophy
Committee Recommends EU Trials of Sarepta’s Elevidys Continue, Day After Holds
One day after the European Medicines Agency requested that three clinical trials of Elevidys be placed on hold after the death of a U.S. teenager, a data monitoring committee concluded that they should continue unchanged.
April 4, 2025
·
2 min read
·
Dan Samorodnitsky
RELIEF THERAPEUTICS Holding SA Announces Results of Extraordinary General Meeting
RELIEF THERAPEUTICS Holding SA announces the results of the extraordinary general meeting of shareholders, which took place in Geneva , Friday, April 26, 2024.
April 26, 2024
·
4 min read
Press Releases
Ferring Unveils New Data with ADSTILADRIN® (nadofaragene firadenovec-vncg) at 112th Annual Meeting of the Japanese Urological Association
April 21, 2025
·
11 min read
Press Releases
Ferring Inc. Receives Health Canada Approval for REBYOTA® (fecal microbiota, live)
March 7, 2025
·
9 min read
Immunology and inflammation
Vyne Crashes After Safety Signal in Dogs Puts Hold on Clinical Trial of Plaque Psoriasis
The hold, placed by the FDA on an early-stage clinical trial of an experimental BET inhibitor, stems from a recent observation of testicular toxicity in canines given the treatment.
April 25, 2025
·
2 min read
·
Tristan Manalac
Pharm Country
Ferring Pharmaceuticals and Posterity Health Launch New Partnership to Activate Men About Their Fertility
Ferring Pharmaceuticals today launched a new Male Fertility program on Ferring’s Fertility Out Loud platform that empowers men to take the initiative to understand their fertility status.
June 20, 2024
·
4 min read
Press Releases
Ipsen S.A. - Formalities for making available and consulting preparatory documents to the 2025 Annual General Meeting
May 1, 2025
·
6 min read
Press Releases
Ferring Announces Initial Data from Phase 3 Trial in Japanese Patients Demonstrating 75% Complete Response Rate at 3 Months with (nadofaragene firadenovec) in BCG-unresponsive NMIBC Patients1
April 21, 2025
·
9 min read
Business
Ferring Pharmaceuticals and SK Pharmteco Enter into Commercial Gene Therapy Manufacturing Deal
Ferring Pharmaceuticals and SK pharmteco today announced an agreement to scale up commercial manufacturing capacity for the drug substance of Ferring’s intravesical non-replicating gene therapy ADSTILADRIN (nadofaragene firadenovec-vncg) for ensuring long-term future supply.
April 18, 2024
·
10 min read
1 of 65,026
Next
